// App-Quantinova.ai

1010 : Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies

Researchers

Presenter

  • Xenofon Baraliakos

Principal Investigators

  • Pedro Machado

  • Lars Bauer

  • Bengt Hoepken

  • Mindy Kim

  • Thomas Kumke

  • Rachel Tham

  • Martin Rudwaleit

Medical Centers

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • Kings College London, London, United Kingdom

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Smyrna, GA

  • UCB Pharma, Slough, UK, Overland Park, KS

  • University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

Locations

  • Germany

  • United Kingdom

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02505542

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved